|
1
|
Dimitrova N, Vukov M and Valerianova Z:
Cancer incidence in Bulgaria. 2013 National Oncological Hospital,
Bulgarian National Cancer Registry, Publisher AVIS-24 Ltd, .
24:1–171. 2015.
|
|
2
|
Balch CM, Soong SJ, Murad TM, Smith JW,
Maddox WA and Durant JR: A multifactorial analysis of melanoma. IV.
Prognostic factors in 200 melanoma patients with distant metastases
(stage III). J Clin Oncol. 1:126–134. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barth A, Wanek LA and Morton DL:
Prognostic factors in 1,521 melanoma patients with distant
metastases. J Am Coll Surg. 181:193–201. 1995.[see comments].
PubMed/NCBI
|
|
4
|
Brand CU, Ellwanger U, Stroebel W, Meier
F, Schlagenhauff B, Rassner G and Garbe C: Prolonged survival of 2
years or longer for patients with disseminated melanoma. An
analysis of related prognostic factors. Cancer. 79:2345–2353. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mössner R, Anders N, König IR, Krüger U,
Schmidt D, Berking C, Ziegler A, Brockmöller J, Kaiser R,
Volkenandt M, et al: Variations of the melanocortin-1 receptor and
the glutathione-S transferase T1 and M1 genes in cutaneous
malignant melanoma. Arch Dermatol Res. 298:371–379. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schoof N, von Bonin F, König IR, Mössner
R, Krüger U, Reich K, Berking C, Volkenandt M, Ziegler A, Böckmann
L, et al: Distal and proximal interleukin (IL)-10 promoter
polymorphisms associated with risk of cutaneous melanoma
development: A case--control study. Genes Immun. 10:586–590. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bishop DT, Demenais F, Iles MM, Harland M,
Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E,
et al: Genome-wide association study identifies three loci
associated with melanoma risk. Nat Genet. 41:920–925. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landi MT, Kanetsky PA, Tsang S, Gold B,
Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M,
Grossman L, et al: MC1R, ASIP, and DNA repair in sporadic and
familial melanoma in a Mediterranean population. J Natl Cancer
Inst. 97:998–1007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dolzan V, Rudolf Z and Breskvar K: Genetic
susceptibility to environmental carcinogenesis in Slovenian
melanoma patients. Acta Dermatovenerol Alp Pannonica Adriat.
15:69–78. 2006.PubMed/NCBI
|
|
10
|
Wei Q, Lee JE, Gershenwald JE, Ross MI,
Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, et al:
Repair of UV light-induced DNA damage and risk of cutaneous
malignant melanoma. J Natl Cancer Inst. 95:308–315. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lear JT, Smith AG, Strange RC and Fryer
AA: Detoxifying enzyme genotypes and susceptibility to cutaneous
malignancy. Br J Dermatol. 142:8–15. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fargnoli MC, Argenziano G, Zalaudek I and
Peris K: High- and low-penetrance cutaneous melanoma susceptibility
genes. Expert Rev Anticancer Ther. 6:657–670. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Howell WM, Turner SJ, Collins A, Bateman
AC and Theaker JM: Influence of TNFalpha and LTalpha single
nucleotide polymorphisms on susceptibility to and prognosis in
cutaneous malignant melanoma in the British population. Eur J
Immunogenet. 29:17–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Passarelli A, Mannavola F, Stucci LS,
Tucci M and Silvestris F: Immune system and melanoma biology: A
balance between immunosurveillance and immune escape. Oncotarget.
8:106132–106142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lázár-Molnár E, Hegyesi H, Tóth S and
Falus A: Autocrine and paracrine regulation by cytokines and growth
factors in melanoma. Cytokine. 12:547–554. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirano T: Interleukin 6 and its receptor:
Ten years later. Int Rev Immunol. 16:249–284. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohl K and Tenbrock K: Inflammatory
cytokines in systemic lupus erythematosus. J Biomed Biotechnol.
2011:4325952011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tobin RP, Jordan KR, Kapoor P, Spongberg
E, Davis D, Vorwald VM, Couts KL, Gao D, Smith DE, Borgers JSW, et
al: IL-6 and IL-8 are linked with myeloid-derived suppressor cell
accumulation and correlate with poor clinical outcomes in melanoma
patients. Front Oncol. 9:12232019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoejberg L, Bastholt L, Johansen JS,
Christensen IJ, Gehl J and Schmidt H: Serum interleukin-6 as a
prognostic biomarker in patients with metastatic melanoma. Melanoma
Res. 22:287–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vlaykova T: Prognostic factors in
metastatic melanoma: special reference to tumor vascularity,
proliferation and Bcl-2 expression. Turku University. (Turku,
Finland). 2002.
|
|
22
|
Linnskog R, Jönsson G, Axelsson L, Prasad
CP and Andersson T: Interleukin-6 drives melanoma cell motility
through p38α-MAPK-dependent up-regulation of WNT5A expression. Mol
Oncol. 8:1365–1378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Na YR, Lee JS, Lee SJ and Seok SH:
Interleukin-6-induced Twist and N-cadherin enhance melanoma cell
metastasis. Melanoma Res. 23:434–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rossi S, Cordella M, Tabolacci C, Nassa G,
D'Arcangelo D, Senatore C, Pagnotto P, Magliozzi R, Salvati A,
Weisz A, et al: TNF-alpha and metalloproteases as key players in
melanoma cells aggressiveness. J Exp Clin Cancer Res. 37:3262018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Donia M, Kjeldsen JW and Svane IM: The
controversial role of TNF in melanoma. OncoImmunology.
5:e11076992018. View Article : Google Scholar
|
|
26
|
Bertrand F, Rochotte J, Colacios C,
Montfort A, Andrieu-Abadie N, Levade T, Benoist H and Ségui B:
Targeting TNF alpha as a novel strategy to enhance CD8+ T
cell-dependent immune response in melanoma? OncoImmunology.
5:e10684952015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhai K, Yang Y, Gao ZG and Ding J:
Interleukin-6-174G>C gene promoter polymorphism and prognosis in
patients with cancer. Oncotarget. 8:44490–44497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banday MZ, Balkhi HM, Hamid Z, Sameer AS,
Chowdri NA and Haq E: Tumor necrosis factor-α (TNF-α)-308G/A
promoter polymorphism in colorectal cancer in ethnic Kashmiri
population - A case control study in a detailed perspective. Meta
Gene. 9:128–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kroeger KM, Steer JH, Joyce DA and Abraham
LJ: Effects of stimulus and cell type on the expression of the −308
tumour necrosis factor promoter polymorphism. Cytokine. 12:110–119.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhuang L, Ma W, Cai D, Zhong H and Sun Q:
Associations between tumor necrosis factor-α polymorphisms and risk
of psoriasis: A meta-analysis. PLoS One. 8:e688272013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Howell WM, Turner SJ, Theaker JM and
Bateman AC: Cytokine gene single nucleotide polymorphisms and
susceptibility to and prognosis in cutaneous malignant melanoma.
Int J Immunogenet. 30:409–414. 2003. View Article : Google Scholar
|
|
32
|
Nikolova PN, Pawelec GP, Mihailova SM,
Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS
and Naumova EJ: Association of cytokine gene polymorphisms with
malignant melanoma in Caucasian population. Cancer Immunol
Immunother. 56:371–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gu F, Qureshi AA, Niu T, Kraft P, Guo Q,
Hunter DJ and Han J: Interleukin and interleukin receptor gene
polymorphisms and susceptibility to melanoma. Melanoma Res.
18:330–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gu F, Qureshi AA, Kraft P, Guo Q, Hunter
DJ and Han J: Polymorphisms in genes involved in DNA repair, cell
growth, oxidative stress and inflammatory response, and melanoma
risk. Br J Dermatol. 161:209–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurzawski M, Pawlik A, Czerny B, Domański
L, Rózański J and Droździk M: Frequencies of the common promoter
polymorphisms in cytokine genes in a Polish population. Int J
Immunogenet. 32:285–291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garbe C, Ellwanger U, Tronnier M, Brocker
EB and Orfanos CE: The New American Joint Committee on Cancer
staging system for cutaneous melanoma: A critical analysis based on
data of the German Central Malignant Melanoma Registry. Cancer.
94:2305–2307. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dickson PV and Gershenwald JE: Staging and
prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 20:1–17.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zarogoulidis P, Yarmus L, Darwiche K,
Walter R, Huang H, Li Z, Zaric B, Tsakiridis K and Zarogoulidis K:
Interleukin-6 cytokine: A multifunctional glycoprotein for cancer.
Immunome Res. 9:165352013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gomes M, Coelho A, Araújo A, Azevedo A,
Teixeira AL, Catarino R and Medeiros R: IL-6 polymorphism in
non-small cell lung cancer: A prognostic value? Tumour Biol.
36:3679–3684. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu C, Vickers MF and Kerbel RS:
Interleukin 6: A fibroblast-derived growth inhibitor of human
melanoma cells from early but not advanced stages of tumor
progression. Proc Natl Acad Sci USA. 89:9215–9219. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fishman D, Faulds G, Jeffery R,
Mohamed-Ali V, Yudkin JS, Humphries S and Woo P: The effect of
novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6
transcription and plasma IL-6 levels, and an association with
systemic-onset juvenile chronic arthritis. J Clin Invest.
102:1369–1376. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Terry CF, Loukaci V and Green FR:
Cooperative influence of genetic polymorphisms on interleukin 6
transcriptional regulation. J Biol Chem. 275:18138–18144. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jones KG, Brull DJ, Brown LC, Sian M,
Greenhalgh RM, Humphries SE and Powell JT: Interleukin-6 (IL-6) and
the prognosis of abdominal aortic aneurysms. Circulation.
103:2260–2265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Martínez-Escribano JA, Moya-Quiles MR,
Muro M, Montes-Ares O, Hernández-Caselles T, Frías JF and
Alvarez-López MR: Interleukin-10, interleukin-6 and
interferon-gamma gene polymorphisms in melanoma patients. Melanoma
Res. 12:465–469. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gautam KA, Muktanand T, Sankhwar SN, Goel
A, Sankhwar PL and Rajender S: Functional polymorphisms in the IL6
gene promoter and the risk of urinary bladder cancer in India.
Cytokine. 77:52–156. 2016. View Article : Google Scholar
|
|
46
|
Leibovici D, Grossman HB, Dinney CP,
Millikan RE, Lerner S, Wang Y, Gu J, Dong Q and Wu X: Polymorphisms
in inflammation genes and bladder cancer: From initiation to
recurrence, progression, and survival. J Clin Oncol. 23:5746–5756.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Datz E, Zeman F, Koller M, Szeimies RM,
Berneburg M, Landthaler M, Bosserhoff AK and Karrer S:
Phototherapy-induced elevation of serum level of melanoma
inhibitory activity. Photodermatol Photoimmunol Photomed.
35:255–260. 2019.PubMed/NCBI
|
|
48
|
Aggarwal BB, Gupta SC and Kim JH:
Historical perspectives on tumor necrosis factor and its
superfamily: 25 years later, a golden journey. Blood. 119:651–665.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Messer G, Spengler U, Jung MC, Honold G,
Blömer K, Pape GR, Riethmüller G and Weiss EH: Polymorphic
structure of the tumor necrosis factor (TNF) locus: An NcoI
polymorphism in the first intron of the human TNF-beta gene
correlates with a variant amino acid in position 26 and a reduced
level of TNF-beta production. J Exp Med. 173:209–219. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wilson AG, di Giovine FS, Blakemore AI and
Duff GW: Single base polymorphism in the human tumour necrosis
factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR
product. Hum Mol Genet. 1:3531992. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kroeger KM, Carville KS and Abraham LJ:
The −308 tumor necrosis factor-alpha promoter polymorphism effects
transcription. Mol Immunol. 34:391–399. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang S, Wang C, Xi B and Li X:
Association between the tumour necrosis factor-α −308G/A
polymorphism and chronic obstructive pulmonary disease: An update.
Respirology. 16:107–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ghaderian SM, Akbarzadeh Najar R and
Tabatabaei Panah AS: Tumor necrosis factor-α: Investigation of gene
polymorphism and regulation of TACE-TNF-α system in patients with
acute myocardial infarction. Mol Biol Rep. 38:4971–4977. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sharma S, Sharma A, Kumar S, Sharma SK and
Ghosh B: Association of TNF haplotypes with asthma, serum IgE
levels, and correlation with serum TNF-alpha levels. Am J Respir
Cell Mol Biol. 35:488–495. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Helmig S, Aliahmadi N, Stephan P, Döhrel J
and Schneider J: TNF-α −308 genotypes are associated with TNF-α and
TGF-β1 mRNA expression in blood leucocytes of humans.
Cytokine. 53:306–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu N, Liu Gj and Liu J: Genetic
association between TNF-α promoter polymorphism and susceptibility
to squamous cell carcinoma, basal cell carcinoma, and melanoma: A
meta-analysis. Oncotarget. 8((32)): 53873–53885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang J, Cao C, Luo H, Xiong S, Xu Y and
Xiong W: Tumour necrosis factor-α −308G/A polymorphism and risk of
the four most frequent cancers: a meta-analysis. Int J
Immunogenetics. 38:311–320. 2011. View Article : Google Scholar
|
|
58
|
Gorouhi F, Islami F, Bahrami H and
Kamangar F: Tumour-necrosis factor-A polymorphisms and gastric
cancer risk: A meta-analysis. Br J Cancer. 98:1443–1451. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang Y, Feng R, Bi S and Xu Y: TNF-alpha
polymorphisms and breast cancer. Breast Cancer Res Treat.
129:513–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Min L, Chen D, Qu L and Shou C: Tumor
necrosis factor-a polymorphisms and colorectal cancer risk: A
meta-analysis. PLoS One. 9:e851872014. View Article : Google Scholar : PubMed/NCBI
|
